Core Viewpoint - Sunflower is planning a significant asset restructuring by acquiring controlling stakes in two companies, aiming to expand its business into the semiconductor materials sector while consolidating its pharmaceutical operations [1][9]. Group 1: Acquisition Details - The company announced plans to acquire controlling rights in Zhangzhou Xipu Materials Technology Co., Ltd. and 40% of Zhejiang Beid Pharmaceutical Co., Ltd. through share issuance and/or cash payment [1]. - The transaction is expected to constitute a major asset restructuring and will not lead to a change in the actual controller of the company [1]. - The stock will be suspended from trading starting September 8, 2025, with the transaction plan to be disclosed within 10 trading days [1]. Group 2: Company Background and Transition - Founded in 2005, Sunflower initially focused on solar energy products but faced performance pressures due to cyclical fluctuations in the photovoltaic industry [6]. - The company has previously attempted to diversify, including a significant asset restructuring in 2019 that led to a 60% stake acquisition in Beid Pharmaceutical, marking its entry into the pharmaceutical sector [7]. - In March 2020, the company rebranded to Zhejiang Sunflower Health Technology Co., Ltd., focusing on the research, production, and sales of pharmaceuticals [7]. Group 3: Financial Performance - In the first half of 2025, the company reported revenues of approximately 144 million yuan, a year-on-year decline of 8.33%, and a net profit of only 1.16 million yuan, down 35.68% [12]. - The financial struggles have prompted the company to explore cross-industry transitions, with the semiconductor materials acquisition seen as a strategic move to leverage high-growth potential in the tech sector [15]. - The company's performance has been declining, with a net profit of 7.83 million yuan in 2024, reflecting a 64.01% year-on-year decrease [14].